• Something wrong with this record ?

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study

S. Lawless, G. Sbianchi, C. Morris, S. Iacobelli, P. Bosman, D. Blaise, P. Reményi, JL. Byrne, J. Mayer, J. Apperley, J. Lund, G. Kobbe, N. Schaap, C. Isaksson, S. Lenhoff, G. Basak, C. Touzeau, KMO. Wilson, S. González Muñiz, C. Scheid, P....

. 2021 ; 21 (10) : 686-693. [pub] 20210524

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22012127

BACKGROUND: The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world outcomes of patients with myeloma. The aim of this study was to compare the outcome according to the different subtypes of myeloma using CALM data. PATIENTS: This study compared overall survival (OS), progression-free survival (PFS), and complete remission (CR) and the impact of novel versus non-novel drug containing induction regimens prior to autologous hematopoietic cell transplantation (HCT) of 2802 patients with "usual" and "rare" myelomas. RESULTS: Our data suggest that IgM and non-secretory myeloma have superior PFS and OS compared with IgD myeloma and outcomes comparable to those for usual myeloma. Patients who received novel agent induction had higher rates of CR prior to transplant. Non-novel induction regimens were associated with inferior PFS but no difference in OS. Although not the primary focus of this study, we show that poor mobilization status is associated with reduced PFS and OS, but these differences disappear in multivariate analysis suggesting that poor mobilization status is a surrogate for other indicators of poor prognosis. CONCLUSION: We confirm that IgD myeloma is associated with the worst prognosis and inferior outcomes compared with the other isotypes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012127
003      
CZ-PrNML
005      
20240516121356.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clml.2021.05.012 $2 doi
035    __
$a (PubMed)34158265
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Lawless, Sarah $u Belfast City Hospital, Belfast, Northern Ireland, United Kingdom. Electronic address: Sarahh.lawless@belfasttrust.hscni.net
245    10
$a IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study / $c S. Lawless, G. Sbianchi, C. Morris, S. Iacobelli, P. Bosman, D. Blaise, P. Reményi, JL. Byrne, J. Mayer, J. Apperley, J. Lund, G. Kobbe, N. Schaap, C. Isaksson, S. Lenhoff, G. Basak, C. Touzeau, KMO. Wilson, S. González Muñiz, C. Scheid, P. Browne, A. Anagnostopoulos, A. Rambaldi, E. Jantunen, N. Kröger, S. Schönland, I. Yakoub-Agha, L. Garderet
520    9_
$a BACKGROUND: The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world outcomes of patients with myeloma. The aim of this study was to compare the outcome according to the different subtypes of myeloma using CALM data. PATIENTS: This study compared overall survival (OS), progression-free survival (PFS), and complete remission (CR) and the impact of novel versus non-novel drug containing induction regimens prior to autologous hematopoietic cell transplantation (HCT) of 2802 patients with "usual" and "rare" myelomas. RESULTS: Our data suggest that IgM and non-secretory myeloma have superior PFS and OS compared with IgD myeloma and outcomes comparable to those for usual myeloma. Patients who received novel agent induction had higher rates of CR prior to transplant. Non-novel induction regimens were associated with inferior PFS but no difference in OS. Although not the primary focus of this study, we show that poor mobilization status is associated with reduced PFS and OS, but these differences disappear in multivariate analysis suggesting that poor mobilization status is a surrogate for other indicators of poor prognosis. CONCLUSION: We confirm that IgD myeloma is associated with the worst prognosis and inferior outcomes compared with the other isotypes.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a transplantace hematopoetických kmenových buněk $x metody $x mortalita $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobulin D $x metabolismus $7 D007072
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $7 D009101
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a analýza přežití $7 D016019
650    _2
$a příprava pacienta k transplantaci $x metody $x mortalita $7 D019172
650    _2
$a autologní transplantace $x metody $x mortalita $7 D014182
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sbianchi, Giulia $u Tor Vergata University of Rome, Rome, Italy
700    1_
$a Morris, Curly $u Queens University of Belfast, Belfast, Northern Ireland United Kingdom
700    1_
$a Iacobelli, Simona $u Tor Vergata University of Rome, Rome, Italy
700    1_
$a Bosman, Paul $u EBMT Data Office Leiden, Leiden, Netherlands
700    1_
$a Blaise, Didier $u Institut Paoli Calmettes, Marseille, France
700    1_
$a Reményi, Péter $u Dél-pesti Centrumkórház, Budapest, Hungary
700    1_
$a Byrne, J L $u Nottingham University, Nottingham, United Kingdom
700    1_
$a Mayer, Jiri $u University Hospital Brno, Brno, Czech Republic
700    1_
$a Apperley, Jane $u Hammersmith Hospital, London, United Kingdom
700    1_
$a Lund, Johan $u Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Kobbe, Guido $u Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany
700    1_
$a Schaap, Nicolaas $u Radboud University Medical Centre, Nijmegen, Netherlands
700    1_
$a Isaksson, Cecilia $u Umeå University Hospital, Umeå, Sweden
700    1_
$a Lenhoff, Stig $u Skanes University Hospital, Lund, Sweden
700    1_
$a Basak, Grzegorz $u Central Clinical Hospital, Warsaw, Poland
700    1_
$a Touzeau, Cyrille $u CHU Nantes, Nantes, France
700    1_
$a Wilson, Keith M O $u St. James's University Hospital of Wales, Cardiff, Wales, United Kingdom
700    1_
$a González Muñiz, Soledad $u Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
700    1_
$a Scheid, Christof $u University of Cologne, Cologne, Germany
700    1_
$a Browne, Paul $u St. James's Hospital, Dublin, Ireland
700    1_
$a Anagnostopoulos, Achilles $u George Papanicolaou General Hospital, Thessaloniki, Greece
700    1_
$a Rambaldi, Alessandro $u Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy $7 xx0317376
700    1_
$a Jantunen, Esa $u University of Eastern Finland, Kuopio, Finland
700    1_
$a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany
700    1_
$a Schönland, Stefan $u University Hospital Heidelberg, Heidelberg, Germany
700    1_
$a Yakoub-Agha, Ibrahim $u Lille University Hospital, Lille, France
700    1_
$a Garderet, Laurent $u Hospital Pitié Salpêtrière, Paris, France
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 21, č. 10 (2021), s. 686-693
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34158265 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20240516121350 $b ABA008
999    __
$a ok $b bmc $g 1789634 $s 1163328
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 21 $c 10 $d 686-693 $e 20210524 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options